Abivax SA American Depositary Shares (ABVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abivax SA American Depositary Shares (ABVX) has a cash flow conversion efficiency ratio of -0.118x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-50.52 Million) by net assets ($429.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Abivax SA American Depositary Shares net asset quality index to measure how much of total assets are equity-financed.
Abivax SA American Depositary Shares - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Abivax SA American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Abivax SA American Depositary Shares (ABVX) long-term investment share to see how much of total assets are deployed in long-term investments.
Abivax SA American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abivax SA American Depositary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
0.036x |
|
Orkla ASA
OL:ORK
|
0.191x |
|
LG Corp
KO:003550
|
0.009x |
|
Assurant Inc
NYSE:AIZ
|
0.114x |
|
Hyundai Rotem Co
KO:064350
|
-0.010x |
|
China Spacesat Co Ltd
SHG:600118
|
0.022x |
|
Mowi ASA
OL:MOWI
|
0.199x |
|
Industrial Bank Of Korea
KO:024110
|
0.054x |
Annual Cash Flow Conversion Efficiency for Abivax SA American Depositary Shares (2014–2025)
The table below shows the annual cash flow conversion efficiency of Abivax SA American Depositary Shares from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see ABVX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $455.01 Million | $-155.69 Million | -0.342x | +90.99% |
| 2024-12-31 | $40.58 Million | $-154.07 Million | -3.796x | -644.06% |
| 2023-12-31 | $196.01 Million | $-100.01 Million | -0.510x | +93.20% |
| 2022-12-31 | $7.19 Million | $-53.94 Million | -7.503x | -326.14% |
| 2021-12-31 | $25.93 Million | $-45.66 Million | -1.761x | -5.67% |
| 2020-12-31 | $17.90 Million | $-29.82 Million | -1.666x | -12.75% |
| 2019-12-31 | $18.59 Million | $-27.47 Million | -1.478x | -250.67% |
| 2018-12-31 | $34.66 Million | $-14.60 Million | -0.421x | -140.29% |
| 2017-12-31 | $48.18 Million | $-8.45 Million | -0.175x | +36.28% |
| 2016-12-31 | $56.72 Million | $-15.61 Million | -0.275x | -32.51% |
| 2015-12-31 | $71.77 Million | $-14.90 Million | -0.208x | -113.23% |
| 2014-12-31 | $33.94 Million | $-3.31 Million | -0.097x | -- |
About Abivax SA American Depositary Shares
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials f… Read more